Mitochondrial metabolism: a predictive biomarker of radiotherapy efficacy and toxicity
F Taghizadeh-Hesary, M Houshyari… - Journal of Cancer …, 2023 - Springer
Introduction Radiotherapy is a mainstay of cancer treatment. Clinical studies revealed a
heterogenous response to radiotherapy, from a complete response to even disease …
heterogenous response to radiotherapy, from a complete response to even disease …
[HTML][HTML] Mitochondrial metabolism: a new dimension of personalized oncology
B Behnam, F Taghizadeh-Hesary - Cancers, 2023 - mdpi.com
Simple Summary Cancer cells are dependent on normal cells for their survival and
functionality because they can use nanoscale tubes to steal the mitochondria from immune …
functionality because they can use nanoscale tubes to steal the mitochondria from immune …
“Reinforcement” by tumor microenvironment: the seventh “R” of radiobiology
F Taghizadeh-Hesary - International Journal of Radiation Oncology …, 2024 - redjournal.org
Radiation therapy is a highly effective method for inhibiting tumor growth and is widely used
in clinical settings. 1 It damages the vital biomolecules (especially DNA) of cancer cells and …
in clinical settings. 1 It damages the vital biomolecules (especially DNA) of cancer cells and …
Nanodelivery systems: An efficient and target‐specific approach for drug‐resistant cancers
S Ashique, A Garg, A Hussain, A Farid… - Cancer …, 2023 - Wiley Online Library
Background Cancer treatment is still a global health challenge. Nowadays, chemotherapy is
widely applied for treating cancer and reducing its burden. However, its application might be …
widely applied for treating cancer and reducing its burden. However, its application might be …
[HTML][HTML] Ciliated, Mitochondria-Rich Postmitotic Cells are Immune-privileged, and Mimic Immunosuppressive Microenvironment of Tumor-Initiating Stem Cells: From …
B Behnam, H Fazilaty, M Ghadyani, P Fadavi… - Frontiers in Bioscience …, 2023 - imrpress.com
Cancer whose major problems are metastasis, treatment resistance, and recurrence is the
leading cause of death worldwide. Tumor-initiating stem cells (TiSCs) are a subset of the …
leading cause of death worldwide. Tumor-initiating stem cells (TiSCs) are a subset of the …
Combined transcriptomics and in-silico approach uncovers the role of prognostic biomarkers in hepatocellular carcinoma
Liver cancer is among the top five death-causing malignancies. High mortality rate, poor
prognosis, and minimal drug options for hepatocellular carcinoma (HCC) patients led to the …
prognosis, and minimal drug options for hepatocellular carcinoma (HCC) patients led to the …
[HTML][HTML] Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor
GM Deng, HB Song, ZZ Du, YW Xue… - World Journal of …, 2024 - ncbi.nlm.nih.gov
BACKGROUND The development and progression of gastric cancer (GC) are closely linked
to the nutritional status of patients. Although immunotherapy has been demonstrated to be …
to the nutritional status of patients. Although immunotherapy has been demonstrated to be …
[HTML][HTML] The Metastatic Spread of Breast Cancer Accelerates during Sleep: How the Study Design can Affect the Results
M Houshyari, F Taghizadeh-Hesary - Asian Pacific Journal of …, 2023 - ncbi.nlm.nih.gov
Metastasis is the most common event that determines survival in patients with breast cancer.
The benefits of appropriate sleep in enhancing cancer patients' prognosis have been …
The benefits of appropriate sleep in enhancing cancer patients' prognosis have been …
[HTML][HTML] Characterization of tumor and immune tumor microenvironment of primary tumors and metastatic sites in advanced renal cell carcinoma patients based on …
SE Rebuzzi, M Brunelli, F Galuppini, VG Vellone… - Cancers, 2023 - mdpi.com
Simple Summary The identification of clinical and tumor factors to identify patients who most
benefit from oncological treatments is a crucial clinical unmet need. We studied differences …
benefit from oncological treatments is a crucial clinical unmet need. We studied differences …
[HTML][HTML] Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy
X Kang, J Wang, X Kang, L Bai - BMC cancer, 2023 - Springer
Background Clinical trials have shown that anti-PD1 therapy, either as a monotherapy or in
combination, is effective and well-tolerated in patients with recurrent or unresectable …
combination, is effective and well-tolerated in patients with recurrent or unresectable …